Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clinical High-Risk Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

NCT03983421
View directory record Official record
Conditions
Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
15 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 22, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 22, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895
View directory record Official record
Conditions
Clinical High Risk for Psychosis (CHR)
Interventions
MT1988 Low Dose, MT1988 High Dose, Placebo
Drug
Lead sponsor
Monument Therapeutics Limited
Industry
Eligibility
17 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

NCT06639074
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

NCT03003520
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 22, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

NCT06947382
View directory record Official record
Conditions
Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Not listed
Lead sponsor
Immunovia, Inc.
Industry
Eligibility
45 Years and older
Enrollment
1,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Burbank, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 22, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135
View directory record Official record
Conditions
Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Interventions
Atovaquone, Biopsy, Computed Tomography, Paracentesis
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

REACH VET Implementation Program Evaluation

NCT03280225
View directory record Official record
Conditions
Suicide
Interventions
External facilitation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
North Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 22, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

NCT06168812
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Glipizide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed No phase listed Observational

Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis

NCT00587236
View directory record Official record
Conditions
Colitis, Ulcerative, Cholangitis, Sclerosing
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

NCT04263363
View directory record Official record
Conditions
Respiratory Complication, Obstructive Sleep Apnea
Interventions
Sugammadex 100 MG/ML [Bridion]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
PepCan, Candin®
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 22, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Not applicable Interventional

PRIME vs Usual Care for Clinical High Risk

NCT02960451
View directory record Official record
Conditions
Clinical High Risk Syndrome for Psychosis
Interventions
PRIME care, Usual care
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 22, 2026, 2:12 PM EDT
Active, not recruiting Not applicable Interventional

Team-Based Home Blood Pressure Monitoring

NCT05488795
View directory record Official record
Conditions
High Blood Pressure, Hypertension
Interventions
Team-Based Home Blood Pressure Monitoring
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 85 Years
Enrollment
5,760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Active, not recruiting Phase 1 Interventional

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

NCT02353819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Ablative Radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

NCT01398462
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
Interventions
CWP232291
Drug
Lead sponsor
JW Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Systematic Management of High Cholesterol Utilizing Computer Monitoring

NCT00133094
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Simvastin, Computer-based decision support technology
Drug · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291694
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00397579
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
DT388IL3
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High-Fidelity Patient Simulation on Clinical Reasoning Skills and Interprofessional Competencies

NCT06549998
View directory record Official record
Conditions
Healthy
Interventions
Interprofessional Simulation Experience
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 22, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Results available

Mitigation of Postoperative Delirium in High-Risk Patients

NCT05777187
View directory record Official record
Conditions
Post-operative Delirium, Decision Support Systems, Clinical, Cognitive Impairment
Interventions
Clinical Decision Support
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 120 Years
Enrollment
7,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

Glutamate Reducing Interventions in Schizophrenia

NCT03321617
View directory record Official record
Conditions
Clinical High Risk for Psychosis
Interventions
Pomaglumetad methionil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 22, 2026, 2:12 PM EDT
Completed Not applicable Interventional

A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)

NCT01198418
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Experimental
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 22, 2026, 2:12 PM EDT